February 22nd 2024
Shortage in hepatitis b virus (HBV) clinical trials within the WHO African region.
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Patient, Provider, and Caregiver Connection™: Prevention and Control of Meningococcal Disease — Individualizing Vaccine Recommendations in Adolescent Populations
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We are Moving Care Forward Today
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Assessing and Improving the Health-Related Quality of Life Among People Who Inject Drugs
February 1st 2024People who inject drugs (PWID) are at a higher risk for hepatitis C and HIV. A new study examined point of care initiatives and how to better support this population with intervention efforts.
Read More
DAAs Reduce Iron Parameters in Patients with Hepatitis C, Hyperferritinemia
January 8th 2024Statistically significant reductions in serum ferritin, transferrin saturation index, and iron levels were observed after treatment, with hyperferritinemia eradicated in nearly all patients treated with DAAs achieving SVR.
Read More
WHO Updates Recommendations for HIV, Hepatitis, STI Interventions in Prisons
July 26th 2023The update refreshes the organization's 2022 guidance on HIV, viral hepatitis, and STI prevention, diagnosis, treatment, and care for key populations, focusing on people in prisons and other closed settings.
Read More
Despite 60% Drop in Hepatitis B Treatment Efficacy, GSK Plans to Continue Trials
November 9th 2022Initially, 28-29% of patients with chronic hepatitis B achieved undetectable virus levels after 24 weeks of treatment with GSK’s bepirovirsen, but this dropped to 9-10% of patients during a phase 2b trial.
Read More